Method of showing progression of AIDS in an ARC patient by treating with Tyr-Gly compositions
AssigneeImreg, Inc.
InventorA. Arthur Gottlieb
Life of this patent
Estimating the term…
Abstract
Purified human leukocyte dialysates are described for treatment of AIDS, ARC, and other immunodeficient conditions. The dialysates are purified by HPLC processes, and are made available in a form that is free of endotoxin and pyrogen. Methods are described for slowing the progression from ARC to AIDS and for alleviating symptoms of AIDS and ARC, by administration of the dialysates. Methods for treating candidiasis and for increasing immune system response to recall antigen, by administration of the dialysates, are also described.
Claims36
A method for slowing clinical progression to AIDS in an ARC patient, comprising administering to said patient an effective dosage amount of YG Product, said YG Product being YG;
- methylated, acetylated, amidified, esterified, or alcoholated YG;
- or a pharmaceutically acceptable salt of any of the foregoing.
A method of treating a person for candidiasis, comprising administering to said person an effective dosage amount of said YG Product.
A method for alleviating at least one of the clinical symptoms of a person suffering from AIDS or ARC, said method comprising administering to said person an effective dosage amount of YG Product, and said symptoms comprising decrease in percentage of T-helper cells, weight loss, diarrhea, tissue breakdown characterized by increase in serum level of uric acid or creatine phosphokinase, and candidiasis, said YG Product being YG;
- methylated, acetylated, amidified, esterified, or alcoholated YG;
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for increasing immune system response of a mammalian subject to recall antigen, comprising administering to said subject an effective dosage amount of said YG Product, said YG Product being YG, methylated, acetylated, amidified, esterified, or alcoholated YG;
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for increasing immune system response of a mammalian subject to recall antigen, comprising administering to said subject an effective dosage amount of Inhibited YG Product, said Inhibited YG Product being said YG Product mixed with bacitracin, puromycin, amastatin, or another means for inhibiting enzymatic hydrolysis of a Tyr--Gly bond.
A method for increasing immune system response of a mammalian subject to recall antigen, comprising administering to said subject an effective dosage amount of Expanded YG Product, said Expanded YG Product being Tyr--X--Gly where X is a D-aminoacid;
- or the foregoing product methylated, acetylated, amidified, esterified, or alcoholated;
- or a pharmaceutically acceptable salt of any of the foregoing.
A method for increasing immune system response of a mammalian subject to recall antigen, comprising administering to said subject an amount of a nonendogenous polypeptide that, as a result of action of at least one endogenous enzyme, metabolizes to an effective dosage amount of YG Product.
A method for increasing a person's endogenous production of modifiers of biological responses produced in leukocytes, comprising administering to said person an effective dosage amount of said YG Product.
A method for increasing immune system response of a mammalian subject to recall antigen to which said subject has previously been exposed, comprising administering to said subject an effective dosage amount of a purified human leukocyte dialysate, purified of substantially all endotoxin and pyrogen, comprising endogenous material possessing intrinsic immunoamplifier activity, where said endogenous material is YG-material or YGG-material, said YG Product being YG;
- methylated, acetylated, amidified, esterified, or alcoholated YG;
- or a pharmaceutically acceptable salt of any of the foregoing;
- and said YGG Product being YGG;
- methylated, acetylated, amidified, esterified, or alcoholated YGG;
- or a pharmaceutically acceptable salt of any of the foregoing.
Dependencies are inferred from the claim text.